Concepedia

Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)

Solange Peters, Enriqueta Felip, Urania Dafni, Amanda Tufman, Matthias Gückenberger, Ruth Álvarez, Ernest Nadal, Annemarie Becker‐Commissaris, Hansjörg Vees, Miklos Pless,

Journal of Thoracic Oncology · 2020 · 136 citations · 10 references

DOIFull text

Open access

Concepts

References

10

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

, , +17

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Pieter E. Postmus, Keith M. Kerr, Matthijs Oudkerk et al. · Annals of Oncology · 2017 · 2.3K citations · Full text

, , +14

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

Simon J. Dovedi, Amy L. Adlard, Grazyna Lipowska‐Bhalla et al. · Cancer Research · 2014 · 1.3K citations · Full text

, , +17

Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer

Jeffrey D. Bradley, Chen Hu, Ritsuko Komaki et al. · Journal of Clinical Oncology · 2019 · 578 citations · Full text

, , +14

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer

Suresh Senan, Anthony Brade, Lu-hua Wang et al. · Journal of Clinical Oncology · 2016 · 437 citations · Full text

, , +14